On May 30, we issued an updated research report on Illumina, Inc. ILMN, a Zacks Rank #3 (Hold) stock. The company’s market opportunities continue to expand owing to accelerated demand from clinical and translational customers. Its recent strategic collaborations are also expected to widen its product portfolio.
Illumina (ILMN) Grows on Innovation & Strategic Partnerships
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться